Chronobiologically explored effects of Telmisartan.

Blood pressure exhibits natural fluctuations over a 24-hour cycle, known as circadian rhythms. These rhythms influence treatment responses and outcomes in hypertension management. Prior research has shown that antihypertensive drugs can alter both the average blood pressure (MESOR) and the amplitude of its circadian pattern. However, the specific effects of Telmisartan, a commonly used angiotensin II receptor blocker, on these rhythms remain unclear. Existing studies have not fully explored how Telmisartan interacts with circadian timing systems when administered at different times of day. This gap motivated the need for a study that examines Telmisartan's effects on blood pressure and related cardiovascular parameters across multiple circadian stages. The study also aimed to determine if low-dose aspirin could enhance or modify these effects. No prior work had resolved how the timing of drug administration impacts its efficacy in reducing circadian amplitude. This uncertainty drove the design of a crossover study to capture these nuances. The study's approach was novel in its use of cosinor analysis to quantify circadian patterns. It also addressed a gap in understanding how drug effects vary with circadian timing.

The study aimed to evaluate the effects of Telmisartan, both alone and in combination with low-dose aspirin, on circadian blood pressure patterns and other cardiovascular parameters in patients with MESOR-hypertension. The specific problem addressed was the lack of detailed understanding of how drug timing influences treatment outcomes. The motivation stemmed from the need to optimize hypertension management through chronopharmacology. The study sought to determine whether Telmisartan could reduce blood pressure and its circadian amplitude. It also aimed to assess whether low-dose aspirin could enhance these effects. The study design allowed for direct comparison of three treatment conditions within the same patient population. The use of cosinor analysis enabled precise quantification of circadian rhythms. The goal was to provide evidence for time-dependent drug effects in hypertension treatment.

The study employed a crossover, double-blind, randomized design with three treatment stages: placebo, Telmisartan alone, and Telmisartan with low-dose aspirin. Each stage lasted 7 days, with treatment administered at different circadian stages relative to awakening. Variables measured included systolic and diastolic blood pressure, heart rate, ejection fraction, intrarenal resistive index, acceleration time, and serum creatinine. Measurements occurred every 3 hours during waking periods. Data were collected at seven distinct time points after awakening. Single cosinor analysis was used to assess circadian rhythms in each variable. Population-mean least squares spectra summarized the data across all patients. Paired t-tests compared MESOR and circadian amplitude across the three treatments. The study design ensured that each patient served as their own control, minimizing inter-individual variability.

Telmisartan reduced both systolic and diastolic blood pressure, as well as the circadian amplitude of these pressures. The MESOR values for blood pressure were significantly lower under Telmisartan treatment. Ejection fraction increased, while intrarenal resistive index and acceleration time decreased. These effects were more pronounced when low-dose aspirin was added to Telmisartan. The resistive index dropped from 0.70 to 0.62 with Telmisartan alone and further to 0.58 with aspirin. Acceleration time decreased from 320 ms to 280 ms with Telmisartan and to 260 ms with aspirin. Serum creatinine levels remained stable across all treatment stages. The study found no significant differences in heart rate across the three treatments. The most notable result was the reduction in circadian amplitude of blood pressure, indicating a more stable blood pressure profile.

The authors concluded that Telmisartan lowers blood pressure and reduces its circadian amplitude in patients with MESOR-hypertension. The addition of low-dose aspirin enhances these effects, particularly in improving cardiac and renal parameters. The study found that Telmisartan increases ejection fraction while decreasing intrarenal resistive index and acceleration time. These findings suggest that Telmisartan may have protective effects on cardiac and renal function. The authors propose that the observed changes in circadian amplitude could lead to better hypertension management. However, they caution that any circadian-stage-dependent effects of Telmisartan require monitoring over longer periods than a single day. The study did not establish whether the observed effects are dose-dependent or specific to the timing of administration. The authors emphasize the need for further research to confirm the long-term benefits of these findings.